TCT 2015: Polymer-Free DES From Medtronic And Biosensors Show Early Promise
This article was originally published in Clinica
Preliminary results from the RevElution trial of Medtronic’s Drug-Filled Stent (DFS) suggest this polymerless metal drug eluting stent may overcome the limitations of current metal and bioabsorbable drug-eluting coronary stents, according to the trial’s co-principal investigator Stephen Worthley of the Royal Adelaide Hospital in Australia.
You may also be interested in...
The Transcatheter Cardiovascular Therapeutics meeting held in San Diego featured late-breaking trials of new stent technologiesincluding TALENT, BIONYX, BIOFLOW-V, SORT-OUT IX, LEADERS FREE II and ReCre8.
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.